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Abstract 
Chronic alcohol (EtOH) binging has been associated with long-term neural adaptations 
that lead to the development of addiction. Many of the neurobiological features of EtOH 
abuse are shared with other forms of binging, like pathological feeding. The drinking-
in-the-dark paradigm (DID) has been used extensively to study the neurobiology of 
EtOH binge-like drinking due to its ability to promote high intakes relevant to human 
behavior. DID can also generate high consumption of other tastants, but this procedure 
has not been fully adapted to study forms of binging behavior that are not alcohol-dri-
ven. In the present study we used a modified version of DID that uses multiple bottle 
availability to promote even higher levels of EtOH drinking in male C57BL/6J mice 
and allows a thorough investigation of tastant preferences. We assessed whether admin-
istration of systemic naltrexone (NTX) could reduce binging on EtOH, sucrose, and 
saccharin separately as well as in combination. Our multiple bottle DID procedure re-
sulted in heightened levels of consumption compared to previously reported data using 
this task. We found that administration of the opioid receptor antagonist NTX reduced 
intakes of preferred, highly concentrated EtOH, sucrose, and saccharin. We also report 
that NTX was able to reduce overall intakes when animals were allowed to self-admin-
ister EtOH, sucrose, or saccharin in combination. Our modified DID procedure provides 
a novel approach to study binging behavior that extends beyond EtOH to other tastants 
(i.e., sucrose and artificial sweeteners), and has implications for the study of the neu-
ropharmacology of binge drinking.  
Keywords: Binge-like drinking, Addiction, Naltrexone, Ethanol, Sucrose, Saccharin  
!3
1. Introduction 
 Obsessive cravings and compulsive intake, often in the face of severe personal 
and medical consequences, are characteristic of drug abuse and binge eating disorders 
(Rehm et al., 2009; Sacks et al., 2015). In the case of alcohol (ethyl alcohol; EtOH), ex-
cessive drinking typically occurs in a binge-like manner (Esser et al., 2014; Kanny et 
al., 2018), where enough EtOH is consumed to reach high blood EtOH concentrations 
(BECs) in relatively short periods of time (National Institute on Alcohol Abuse and Al-
coholism, 2004). Rates of binge-drinking are high, with 50-90% of all EtOH consumed 
taking the form of binge episodes in adults and underage adolescents, respectively 
(Patrick and Schulenberg, 2013; Goings et al., 2019). Binge drinking is associated with 
accidental injury (Gonzales et al., 2014; Stahre et al., 2014), high blood pressure (Hayi-
bor et al., 2019), increased risk for stroke (Sundell et al., 2008), Type-2 Diabetes 
(Pietraszek et al., 2010), and liver dysfunction (Rosoff et al., 2019). Recurrently engag-
ing in binge drinking may also induce long-term neuroadaptations that further promote 
binging and can lead to the development of addiction (Melendez, 2011; Sprow and 
Thiele, 2012; Carnicella et al., 2014; Tavolacci et al., 2019). Better understanding of the 
neurobiological consequences that arise from repeated intermittent exposure to EtOH 
via binging can lead to improved interventions and outcomes for addiction.  
 Animal models of EtOH drinking have been developed in an effort to parallel 
key features of human consumption. Some models have faced criticism due to lack of 
voluntary drinking and low levels of consumption that do not reach pharmacologically 
significant BECs (Rhodes et al., 2005; Thiele and Navarro, 2014). One model known as 
drinking-in-the-dark (DID) takes advantage of rodents’ natural circadian rhythms in or-
der to promote high levels of voluntary EtOH drinking (Rhodes et al., 2005). Using this 
methodology, EtOH-preferring mice consume enough EtOH to show behavioral and 
pharmacological signs of intoxication that are relevant to human behavior, illustrating 
the face validity of this procedure (Rhodes et al., 2005; Thiele and Navarro, 2014; Jean-
blanc et al., 2018). Although DID has primarily been used to study the neurobiology of 
binge-like EtOH drinking, it can also produce elevated consumption of other drugs of 
abuse, including methamphetamine (Fultz et al., 2017) and opioids (Szumlinski et al., 
2019) and other tastants like sugar (Kamdar et al., 2007; Cozzoli et al., 2012; Giardino 
and Ryabinin, 2013; Holgate et al., 2017). Although a more thorough investigation of 
the conditions that elicit binging on sweet tastants has not been conducted, DID’s ability 
to promote elevated intake points at this paradigm’s potential for understanding com-
mon alterations that result from binging on EtOH and other palatable rewards. 
Alcohol abuse has been proposed to share many neurobiological mechanisms 
with other pathological forms of consumption, including high-calorie sweet foods (Ave-
na, et al., 2012a,b; Schulte et al., 2015, 2016). A strong correlation between high levels 
of EtOH intake and sweet food consumption has been shown in humans (Kampov-
Polevoy et al., 1999; Leggio et al., 2011). Preference for strong sweet solutions has also 
been shown to be associated with a paternal history of alcohol dependence (Kampov-
Polevoy et al., 2001, 2003). This history of dependence has additionally been identified 
as a significant predictor of ‘sugar-addiction’ in children, suggesting a close link be-
tween alcoholism and high sweet-preference with some heritable aspects (Fortuna, 
2010). Similar findings have been observed in rodents and other preclinical models. For 
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example, strains of mice that voluntarily consume high levels of EtOH such as C57BL/
6J (B6) show higher preference indices for sucrose in comparison to other strains 
(Bachmanov et al., 1996, 2001). Rats characterized as ‘sugar-dependent’ show enhanced 
intake of unsweetened EtOH solutions (Avena et al., 2004). Mice sensitized to the psy-
chomotor effects of EtOH display altered patterns of sucrose consumption, showing a 
more rapid initial approach and consumption of sucrose in EtOH-sensitized groups, 
suggesting that EtOH-induced neuroplasticity can affect consummatory behaviors for 
sweet rewards (Pastor et al., 2010).  
 EtOH and sweet tastants like sugar share chemosensory mechanisms of action 
(Di Lorenzo et al., 1986; Scinska et al., 2000) and significantly overlap in their actions 
on brain reward systems (Bodnar, 2019; Olszewski et al., 2019), including the endoge-
nous opioid system. Rewards like EtOH and sugar may exert powerful effects on plea-
sure ‘liking’ via coordinated actions on brain opioid receptors within a network of hedo-
nic ‘hotspots’ (Berridge and Kringelbach, 2015; Castro and Berridge, 2017). Excessive 
binging on sugar or EtOH, to the point of generating signs of dependence, can produce 
negative affective states of withdrawal that are opioid-dependent (Colantuoni et al., 
2002; Avena et al., 2009; Berger et al., 2013). Opioid receptors, and in particular the mu 
receptor can also influence the motivational and psychomotor stimulant effects of EtOH 
and other reinforcers (Gianoulakis, 2001; Pastor et al., 2005, 2011; Pastor and Aragon, 
2006; Kamdar et al., 2007). Pharmacological activation of mu-opioid receptors can en-
hance saccharin or EtOH intakes (Zhang and Kelley, 2002), while inactivation can re-
duce consumption of sucrose, saccharin or EtOH (June et al., 2004; Kamdar et al., 2007; 
Tarragón et al., 2012; Avena et al., 2014; Morales et al., 2017). The opioid receptor an-
tagonist naltrexone (NTX), a compound with high affinity for mu-opioid receptors, is 
used to treat alcoholism (Volpicelli et al., 1992; Kiefer et al., 2003; Jonas et al., 2014), 
and in combination with bupropion (marketed as Contrave™) has recently been ap-
proved for the treatment of binge-eating disorder and weight-loss management. With B6 
mice and a dose range of 2-8 mg/kg, previous data have shown that NTX can reduce 
EtOH binge-like intake using the DID model, although some sex differences have been 
reported (Kamdar et al., 2007; Tarragón et al., 2012; Zhou et al., 2019; Navarro et al., 
2019). It is important to mention, however, that doses of NTX as high as 10 mg/kg have 
failed to reduce EtOH intake in mice selected for high blood EtOH levels (HDID lines) 
obtained using the DID model (Crabbe et al., 2017). HDID lines show remarkably high 
EtOH intakes (Crabbe et al., 2014). Higher doses of NTX might be therefore needed to 
reduce high binge-like EtOH intakes. Overall, although more research is needed, cumu-
lative evidence on the effects of NTX on both EtOH and palatable food binging sug-
gests that this compound can be a highly useful tool to explore the predictive validity of 
a preclinical model.  
 The present study was designed to investigate whether a modified multiple bot-
tle DID paradigm could be used to study similarities in the neural alterations that result 
from binging on EtOH, sucrose, and saccharin. This concurrent multiple bottle (three or 
four bottles) procedure has several advantages over previous one and two-bottle itera-
tions. Concurrent access to multiple bottles, whether in the same or different concentra-
tions can produce magnified intakes (Serra et al., 2003; Tordoff and Bachmanov, 2003a; 
Bell et al., 2006; Rodd et al., 2009; Cozzoli et al., 2012; Colombo et al., 2014; Fultz et 
al., 2017), so this paradigm has the capacity to increase the likelihood of binging behav-
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ior. In addition, it also allows for the investigation of the effects of various concentra-
tions on preference and intake. We used the modified DID model to show elevated con-
sumption of EtOH and other powerful natural reinforcers. Given that the effects of NTX 
have been consistently shown to reduce binge-like behavior, we administered systemic 
NTX in order to determine whether it could not only reduce binge-like consumption of 
EtOH, sucrose, and saccharin but also alter preference for various concentrations.  
  
2. Materials and Methods 
      
2.1 Animals 
      
 A total of 136 male C57BL/6J (B6) mice (JAX® mice strain purchased through 
Charles River Laboratories España S.A., Barcelona, Spain) were used in the present 
study. Animals were 8 weeks old at the time of arrival. They were individually housed 
(with no enriched environment) and kept on a standard 12-h light/dark cycle with lights 
on at 8:00 AM. Colony rooms were maintained at 21 ± 1°C of temperature and 50 ± 5% 
humidity levels. Food and water were provided ad libitum throughout the study unless 
otherwise indicated. Mice were acclimated to housing and colony conditions for 2 
weeks before experiment initiation. All experiments were conducted in accordance with 
the guidelines provided by the European Community Council Directive (2010/63/EU) 
for the use of laboratory animal subjects and approved by the Animal Care Committee 
of Universitat Jaume I. 
2.2 Drugs and Drinking Solutions 
 EtOH, sucrose and sodium saccharin were used as drinking solutions. EtOH 
(99.8%) solutions (PanReac AppliChem, Barcelona, Spain) diluted to 5, 10, 20, 30 or 
40% (v/v) were prepared in sterilized tap water. Sucrose solutions were prepared by dis-
solving ≥ 99.5% sucrose (Sigma-Aldrich Química S.A. Madrid, Spain) in sterilized tap 
water to 5, 10, 20 or 40% (w/v). Sodium saccharine (Sigma-Aldrich, ≥ 98%) solutions 
at 0.13, 0.26, 0.53 or 1.06% (w/v) were dissolved in sterilized tap water. Concentrations 
of all drinking solutions were based on previous studies (Rhodes et al., 2005, 2007; 
Kamdar et al., 2007; Pastor et al., 2011; Tarragón et al., 2012) as well as on our own 
pilot studies. In the case of EtOH, a direct study of the influence of availability of dif-
ferent concentrations and number of tubes was included in the present study (Experi-
ment 1). NTX hydrochloride (Sigma-Aldrich) was diluted in 0.9% physiological saline 
and administered intraperitoneally (IP; 10 mL/kg injection volume). The dose range of 
NTX (4, 8 or 16 mg/kg) used in the present study was based on previous work (Kamdar 
et al., 2007; Tarragón et al., 2012; Fultz et al., 2017). 
      
2.3 Experimental Design 
 To evaluate binge-like drinking we used a modified version of the 4-day DID 
procedure introduced by Rhodes et al. (2005) in which B6 mice drink EtOH voluntarily 
to the point of behavioral intoxication (Rhodes et al., 2005, 2007; Kamdar et al., 2007, 
Lowery et al., 2010; Fultz et al., 2017). Three hours after the start of the dark cycle, wa-
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ter tubes were replaced with 10 mL graduated (0.1 mL increments) cylinders with dou-
ble-ball bearing sipper tubes containing different solutions depending on the experi-
ment. For each experiment (except for Experiment 1), 4 drinking cycles (one per week) 
of 4 days were used. During the first 3 days of each cycle, drinking tubes were available 
for 2 h, then replaced with home cage water bottles. On day 4 (test day), tubes were 
available for 4 h, then replaced with water. Food was not removed when EtOH, sucrose 
or saccharin tubes were introduced. Days 1-3 provided habituation to the procedure. On 
day 4 (Experiments 2-6; intakes recorded at 2 and 4 h) animals received IP injections of 
NTX (0, 4, 8 or 16 mg/kg) 30 min before water tubes were replaced with drinking solu-
tions. We used a counterbalanced, within-subject design; all subjects received all doses 
of NTX, one per week (avoiding ascending or descending dose schedules). For each cy-
cle, habituation was conducted Tuesday-Thursday, with test on Friday. Animals were 
left undisturbed (with regular food/water availability) for 3 days a week; Saturday-
Monday. No significant intake differences between cycles (weeks) were found. Body 
weights were recorded on test days. Rack-mounted empty cages with solution tubes 
were used as a control and correction for leakage. With double-ball bearing sipper tubes 
leaks were rare and minimal (i.e., 0.1 mL). 
 Experiment 1 evaluated DID intake using different EtOH concentrations and 
tube availability configurations (n = 12-15 per group). For this experiment, drinking 
was only assessed for one cycle. Following previous results (Cozzoli et al., 2012; Fultz 
et al., 2017), single and multiple tube configurations were used with different groups. 
EtOH 20% and 40% were tested using one single tube. Using three simultaneously 
available tubes, animals were offered EtOH 5%, 10% and 20%, and also EtOH 20%, 
30% and 40%. Using four concurrently available tubes, animals had access to EtOH 
5%, 10%, 20 and 40%. This experiment allowed us to select a multiple-tube choice ver-
sion of the DID model that produced high EtOH intake.  
Given that we wanted to evaluate the effects of NTX on intake and concentra-
tion preference of EtOH, sucrose or saccharin, a multiple tube choice procedure was 
used for all substances. The effects of NTX on EtOH, sucrose or saccharin intake were 
determined using 4 simultaneously available tubes. EtOH 5%, 10%, 20% and 40% (Ex-
periment 2, n = 15), sucrose 5%, 10%, 20% and 40% (Experiment 3, n = 15) or saccha-
rin 0.13%, 0.26%, 0.53% or 1.06% tubes (Experiment 4, n = 16) were placed using a 
counterbalanced order of concentrations that was changed every day to avoid prediction 
of tube placement. Complete ascending or descending arrangements of concentration 
tubes were also avoided. A separate experiment (Experiment 5; n = 9) to test the effect 
of NTX on water intake was conducted. This experiment followed the same design 
(four cycles of a 4-day DID procedure) and doses described for Experiments 1-3, except 
that 4 drinking tubes containing water were used. In Experiment 6 (n = 15), we were 
interested in evaluating the effects of NTX on intake using a procedure involving simul-
taneously available sucrose, saccharin and EtOH (3 tubes). Animals could choose to 
drink 5% sucrose, 0.13% saccharin or 20% EtOH. Given the strong preference for sweet 
solutions, the two lowest sucrose and saccharin solutions were used against the pre-
ferred EtOH concentration (20% EtOH; based on Experiment 2 results; mL). 
2.4 Data analysis 
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 Data were analyzed using GraphPad Prism 8 software (GraphPad Software Inc., 
San Diego, CA, USA). Time period and/or NTX dose were the independent variables. 
The dependent variables were intakes of EtOH, sucrose or saccharin (mL, g/kg) in Ex-
periments 1-4, intake of water (mL) in Experiment 5, and intake of sucrose, saccharin 
plus EtOH (mL, mL/g) in Experiment 6. In Experiment 5 all tubes contained water; wa-
ter intake was therefore only analyzed as total mL drunk. Due to the substantial differ-
ences in g of EtOH, sucrose or saccharin contained per mL of these substances, intakes 
adjusted per body weight in Experiment 6 were expressed as mL/g, instead of g/kg. As 
described before (Morales et al., 2017), given that we used a within-subjects pharmaco-
logical design, the effects of NTX were analyzed using repeated measures Analysis of 
Variance (ANOVA). Apart from time (first 2 h vs. second 2 h), different simultaneously 
available concentrations or solutions were also considered repeated factors. Experiment 
1 was analyzed using a one-way ANOVA. Post-hoc comparisons were conducted using 
using Tukey's HSD tests. The level for significance (α) for all statistical tests was set at 
0.05. 
3. Results 
3.1 Intake as a function of EtOH concentration and tube availability: comparison to sin-
gle tube DID  
Figure 1 shows EtOH intakes (g/kg; 4 h) of separate groups of animals that were 
offered EtOH under five different tube/concentration configurations. A one-way ANO-
VA [F4,61 = 18.03, p < 0.01] revealed a significant effect of tube condition. From the two 
single tube groups (A and B), those that had access to 40% EtOH showed increased in-
take EtOH (p < 0.05, compared to 20% EtOH). The two groups with the highest con-
centrations available (D, E), with three (20%, 30% and 40%) and four (5%, 10%, 20% 
and 40%) tubes respectively also showed the highest intakes (p < 0.01, compared to 
20% EtOH). Group E was also different from group B (p < 0.05) and showed the high-
est intake during the first 2 h (data not shown) of the 4-h period. Respect to intakes per 
concentration in multiple tube groups, with concurrently available 5%, 10% and 20% 
EtOH tubes (group C), most of their intake came from the 20% tube (3.63 g/kg; 71.6% 
of total intake). With 20%, 30% and 40% EtOH (group D), intake from the three differ-
ent tubes was similar; 2.58 g/kg from EtOH 20%, 3.03 g/kg from EtOH 30% and 2.95 
g/kg from EtOH 40%, representing 30.14%, 35.40% and 34.46% of total intake, respec-
tively. With four tubes (group E), animals obtained most of the g/kg from EtOH 20% 
(3.3 g/kg; 36.7%) and EtOH 40% (4.77 g/kg; 52.5%).  
3.2 Effects of NTX on EtOH consumption  
Table 1 shows the effects of NTX on volumes of EtOH drinking (mL). We first 
assessed whether NTX reduced total EtOH consumption by combining all EtOH con-
centrations. Over the entire 4-h period (top panel), a one-way ANOVA revealed that 
NTX reduced EtOH drinking [F3,42 = 10.7, p < 0.01]. Both 8 mg/kg (p < 0.05) and 16 
mg/kg (p < 0.01) suppressed EtOH intake relative to saline, although 16 mg/kg also dif-
fered from 4 mg/kg (p < 0.01). We also assessed whether NTX differentially suppressed 
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total intakes during the first and second 2-h periods. Using a two-way ANOVA (dose x 
time), we found main effects of time [F1,14 = 5.57, p < 0.05] and NTX dose [F3,42 = 
10.35, p < 0.01] with no interaction, suggesting that EtOH drinking was higher in the 
first 2-h period and NTX suppressed the volume of EtOH drank. We further assessed 
whether NTX altered drinking as a function of concentration. For the first 2 h of intake, 
a two-way ANOVA (concentration x dose) revealed significant effects of concentration 
[F3,42 = 14.76, p < 0.01], NTX dose [F3,42 = 7.85, p < 0.01] and an interaction between 
factors [F9,126 = 2.4, p < 0.05]. Under baseline conditions, mice equally sampled be-
tween 40% and 20% EtOH, which were both preferred to the 5% option (p < 0.01). 
However, 8 mg/kg (p < 0.01, compared to NTX 0) and 16 mg/kg (p < 0.01, compared to 
0 and 4 mg/kg) NTX treatments selectively reduced this preference by suppressing in-
take of the 20% solution. We found similar results over the second 2-h period, with sig-
nificant effects of concentration [F3,42 = 8.97, p < 0.01], dose [F3,42 = 5.66, p < 0.01] and 
interaction between factors [F9,126 = 3.49, p < 0.05]. However, unlike the first 2-h peri-
od, during which both 40% and 20% were sampled, 20% was the most preferred con-
centration of EtOH (p < 0.01 relative to 5% and 10%). The highest NTX dose abolished 
this preference by reducing intake of 20% EtOH (p < 0.01, compared to 0 and 4 mg/kg). 
Over the total 4-h period, we found main effects of concentration [F3,42 = 16.67, p < 
0.01], dose [F3,42 = 10.7, p < 0.01] and an interaction between factors [F9,126 = 4.38, p < 
0.01]. 20% EtOH intake was preferred to 5% and 10% EtOH (p < 0.01) under baseline 
conditions. While 8 mg/kg NTX reduced 20% and 40% EtOH intake (compared to 0 
mg/kg, p < 0.01), high NTX only suppressed 20% EtOH consumption (compared to 0 
and 4 mg/kg, p < 0.01). 
Figure 2 shows the effects of NTX on EtOH intake (g/kg). The same analyses 
described for volume intake (ml) were performed; first with all concentrations com-
bined (panel A) and then including EtOH concentration (panels B, C, D). Figure 2A; for 
the first and second 2-h periods, a two-way ANOVA (time x NTX) showed main effects 
of time [F1,14 = 4,62, p < 0.05] and NTX dose [F3,42 = 8.12, p < 0.01], but no significant 
interaction between time and dose. An effect of NTX (one-way ANOVA) was also 
found for the total 4-h period [F3,42 = 7.87, p < 0.01]. Intakes at 8 and 16 mg/kg; p < 
0.01 different respect to NTX 0 mg/kg. NTX 16 mg/kg was also different from 4 mg/kg 
(p < 0.01). Figure 2B shows intake (as a function of EtOH concentration) during the 
first 2 h. A two-way ANOVA revealed significant effects of dose [F3,42 = 9.40, p < 0.01] 
concentration [F3,42 = 69.44, p < 0.01] and interaction between factors [F9,126 = 3.71, p < 
0.01]. In saline-treated animals, intakes of EtOH 20% and 40% were both higher than 
5% and 10% (p < 0.01) and a difference between EtOH 20% and 40% was also found (p 
< 0.01). In animals treated with NTX 4 mg/kg, EtOH 20% was different from 5% (p < 
0.01) and 10% (p < 0.05), and EtOH 40% was different from all other concentrations (p 
< 0.01). In NTX 8 mg/kg-treated groups, 20% EtOH was different from 5% (p < 0.05), 
and 40% EtOH was different from 5% and 10% (p < 0.01). With 16 mg/kg, 40% EtOH 
was different from the other three concentrations (p < 0.01). At 20% EtOH, NTX 16 
mg/kg reduced intake (compared to NTX 0 mg/kg; p < 0.01). At 40% EtOH, NTX 8 
mg/kg was different from 0 mg/kg and 4 mg/kg (p < 0.01), and NTX 16 mg/kg was dif-
ferent from 0 mg/kg (p < 0.01) and 4 mg/kg (p < 0.05). Data from the second 2-h period 
are shown in figure 2C; a two-way ANOVA revealed significant effects of NTX [F3,42 = 
3.28, p < 0.05] and concentration [F3,42 = 32.01, p < 0.01]. The interaction was p = 
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0.058. Analysis of total intake (4-h period; figure 2D) showed significant effects of dose 
[F3,42 = 7.87, p < 0.01], concentration [F3,42 = 58.07, p < 0.01] and interaction [F9,126 = 
3.04, p < 0.01]. In NTX 0 mg/kg and 4 mg/kg groups, 20% and 40% EtOH were differ-
ent from 5% and 10% (p < 0.01), and differences between 20% and 40% were also 
found (p < 0.01). In NTX 8 mg/kg groups, EtOH 40% was different from 5% and 10% 
(p < 0.01). In NTX 16 mg/kg groups, EtOH 40% was different from all other concentra-
tions (p < 0.01). NTX 8 mg/kg reduced 40% EtOH intake (different from NTX 0 and 4 
mg/kg; p < 0.05) and NTX 16 mg/kg reduced 20% EtOH intake (different from NTX 0 
mg/kg; p < 0.01). 
3.3 Effects of NTX on sucrose intake 
      
The top panel of Table 2 shows the effects of NTX on total mL of sucrose con-
sumed (collapsed across concentrations). A two-way ANOVA (dose x time) revealed 
main effects of dose [F3,42 = 7.77, p < 0.01] and time [F1,14 = 7.31, p < 0.05], in addition 
to an interaction [F3,42 = 9.63, p < 0.01]. For the 4-h period, NTX also reduced volume 
of sucrose drinking [F3,42 = 7.95, p < 0.01]. NTX 8 mg/kg reduced sucrose drinking rel-
ative to saline (p < 0.05), while 16 mg/kg suppressed sucrose compared to vehicle (p < 
0.01) and 4 mg/kg (p < 0.05). We then assessed how NTX affected intake of the differ-
ent concentrations. We found an effect of NTX [F3,42 = 15.95, p < 0.01], concentration 
[F3,42 = 252.80, p < 0.01] and dose x concentration interaction for the first 2-h [F9,126 = 
11.24, p < 0.01]. Under baseline conditions, 40% sucrose was preferred above the three 
alternatives (p < 0.01), and NTX selective reduced drinking of the 40% solution (p < 
0.01). We found no effect of NTX on the second 2-h period, although there was a con-
centration effect [F3,42 = 218.90, p < 0.01]. Finally, our analysis showed main effects of 
dose [F3,42 = 6.84, p < 0.01], concentration [F3,42 = 346.50, p < 0.01], and an interaction 
[F9,126 = 4.05, p < 0.01] when the 0-4 h time period was analyzed. Pairwise comparisons 
showed that NTX 8 and 16 mg/kg reduced 40% sucrose intake (p < 0.01, compared to 
saline). 
Figure 3 shows the effects of NTX on sucrose intake in g/kg. Analyses of time 
period effects on total intake (two-way ANOVA; figure 3A) revealed effects of time 
[F1,14 = 6.12, p < 0.05], dose [F3,42 = 6.58, p < 0.01] and an interaction between factors 
[F3,42 = 8.64, p < 0.01]. NTX 8 and 16 mg/kg reduced intake during the first, but not 
second 2-h period (p < 0.05, compared to saline). A significant effect of NTX (one-way 
ANOVA) was found for the 4-h period [F3,42 = 5.61, p < 0.01]. NTX 8 and 16 mg/kg 
were also different from saline (p < 0.05). Panels B, C and D represent concentration-
dependent effects for 0-2 h, 2-4 h and 0-4 h periods, respectively. Concentration was a 
significant factor on both time periods (figures 3B and 3C; two-way ANOVA), 0-2 h 
[F3,42 = 275.10, p < 0.01] and 2-4 h [F3,42 = 285.80, p < 0.01]. However, an effect of 
NTX was only seen during the first 2 h [F3,42 = 15.47, p < 0.01]. An interaction between 
factors was also found to be significant [F9,126 = 13.49, p < 0.01]. NTX 8 and 16 mg/kg 
reduced sucrose 40% intake (p < 0.01 compared to saline and 4 mg/kg). Figure 3D 
shows 0-4 h intake; significant effects of NTX [F3,42 = 6.67, p < 0.01], concentration 
[F3,42 = 464.90, p < 0.01] and interaction [F9,126 = 5.61, p < 0.01] were found. For su-
crose 40%, NTX 8 and 16 mg/kg were different from saline (p < 0.01), and NTX 8 mg/
kg was also different from NTX 4 mg/kg (p < 0.05). 
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3.4 Effects of NTX on saccharine consumption  
      
When collapsed across concentration (mL data; Table 3), an effect of time [F1,15 
= 8.26, p < 0.05] and a time x dose interaction were found [F3,45 = 5.10, p < 0.01]. NTX 
16 mg/kg (Table 3, top section) only reduced intake during the first 2-h period (p < 
0.05). For the total 4 h, no main effects of NTX were found. We further assessed 
whether NTX differentially reduced drinking of specific saccharine concentrations 
(dose x concentration), which is presented in the bottom panels of Table 3. Both NTX 
[F3,45= 3.10, p < 0.05] and concentration [F3,45 = 15.14, p < 0.01] influenced saccharine 
drinking, showing an interaction [F9,135 = 2.21, p < 0.05]. Under baseline, 4 mg/kg, and 
8 mg/kg NTX treatment, mice preferred the highest saccharin concentration (p < 0.01), 
consuming nearly 50% of total mL from this solution. Only the highest dose of NTX 
suppressed drinking of the preferred saccharine concentration (p < 0.01 relative to 
saline). We found no main effect of NTX on saccharine drinking during the second time 
period, despite a main effect of concentration [F3,45 = 15.59, p < 0.01], and a saccharine 
x NTX interaction [F9,135 = 2.35, p < 0.05]. Whereas the highest concentration of sac-
charine (1.06%) was preferred under control conditions, 16 mg/kg NTX altered this 
preference; it increased intake of 0.53% saccharin relative to 0 mg/kg during the second 
time period (2-4 h; p < 0.01). 
Figure 4 shows the effects of NTX on saccharine intake (g/kg). Analysis of total 
intake data (figure 4A) including the two 2-h periods (time x dose) revealed a signifi-
cant interaction between factors [F3,45 = 5.06, p < 0.01]. Main effects of NTX or time 
were not significant (time factor effect, p = 0.052). NTX 16 mg/kg was different from 
saline (first 2-h; p < 0.05). Total 4-h analysis showed an effect of NTX [F3,45 = 3.30, p < 
0.05], with the highest dose of NTX reducing intake compared to saline (p < 0.05). Fig-
ures 4B, C and D represent data by concentration for the 0-2 h, 2-4 h and 0-4 h time pe-
riods, respectively. Figure 4B; a two-way ANOVA (NTX x concentration) showed sig-
nificant effects of NTX [F3,45 = 5.56, p < 0.01], concentration [F3,45 = 54.66, p < 0.01] 
and interaction between factors [F9,135 = 4.58, p < 0.01]. At saccharin 1.06%, NTX 8 
and 16 mg/kg were found to be different from NTX 0 mg/kg (p < 0.05 and p < 0.01 re-
spectively). For the second 2 h (figure 4C), only a main effect of concentration was 
found [F3,45 = 51.19, p < 0.01]. Figure 4D depicts concentration-dependent effects of 
NTX during the total 4 h period. A two-way ANOVA (NTX x concentration) revealed 
an effect of concentration [F3,45 = 56.49, p < 0.01] and an interaction factors [F9,135 = 
3.94, p < 0.01]. Post-hoc comparisons showed significant differences between NTX 0 
and 16 mg/kg (saccharin 1.06%, p < 0.01). 
3.5 Effects of NTX on water intake  
 NTX administration did not affect water consumption (mL). With data including 
the two separate 2-h periods, a two-way ANOVA (time period x NTX dose) revealed an 
effect of time [F1,8 = 8.76, p < 0.05] but no effects of NTX or interaction between fac-
tors. NTX was also found to produce no effects on water intake when total 4-h data 
were analyzed. Group means (mean ml ± SEM) during the first 2 h were 0.67 ± 0.08, 
0.74 ± 0.07, 0.67 ± 0.09 and 0.61 ± 0.06 (NTX 0, 4, 8 and 16 mg/kg respectively). In-
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takes from the second 2 h period were 0.53 ± 0.08, 0.51 ± 0.07, 0.51 ± 0.08 and 0.56 ± 
0.05 (NTX 0, 4, 8 and 16 mg/kg). Total 4 h consumption was 1.20 ± 0.11, 1.26 ± 0.12, 
1.18 ± 0.10 and 1.18 ± 0.05 (NTX 0, 4, 8 and 16 mg/kg). 
      
3.6 Effects of NTX on simultaneously available sucrose, saccharin and EtOH consump-
tion   
The top panel (Table 4) presents combined intakes from the three tubes (mL) 
during the two separate 2-h periods as well as total 4-h period. We found a main effect 
of NTX [F3,42 = 7.03, p < 0.01] on combined drinking but there was no time x NTX in-
teraction. Total volume consumption over 4-h testing was reduced following administra-
tion of all NTX doses (p < 0.01 for NTX 4 and 8, and p < 0.05 for NTX 16 mg/kg). We 
then analyzed whether NTX treatment selectively affected drinking of the various tas-
tants using a two-way ANOVA (dose x tastant). An effect of tastant was found for the 
first [F2,28 = 137.10, p < 0.01] and second [F2,28 = 146.40, p < 0.01] time periods.  For 
the second 2-h period, an effect of NTX was also found [F3,42 = 10.26, p < 0.01]. No 
interactions between factors were found for both periods. Analysis of total 4-h intakes 
with the three separate tastants (dose x tastant) showed effects of tastant [F2,28 = 182.70, 
p < 0.01] and NTX [F3,42 = 7.03, p < 0.01], but no interaction. With data adjusted to 
body weight (Figure 5; ml/g), analysis of intakes combining all solutions (Figure 5A; 
dose x time) showed an effect of NTX [F3,42 = 6.35, p < 0.01], but no effects of time or 
dose x time interaction. Pairwise tests (0-4 h) showed that all NTX doses reduced total 
intake; p < 0.05 for NTX 4 and 16, and p < 0.01 for NTX 8 mg/kg. When the three dif-
ferent solutions were analyzed separately we found an effect of tastant for both, first 
[F2,28 = 109.40, p < 0.01] and second [F2,28 = 140.10, p < 0.01] 2-h periods (Figures 5B 
and C, respectively) but no significant interactions between NTX and tastant. An effect 
of NTX was also found on the second period [F3,42 = 11.74, p < 0.01]. Similarly, main 
effects of drinking solution [F2,28 = 166.11, p < 0.01] and NTX [F3,42 = 6.35, p < 0.01] 
were found for the total 4-h period (Figure 5D), without a significant interaction.  
4. Discussion 
Understanding the brain mechanisms by which vulnerable individuals develop 
unmanageable patterns of consumption of food or alcohol is key in order to improve 
treatments and prevent addiction. Over the last decade an increasing number of studies 
have used animal models that attempt to mimic binge intake (Thiele and Navarro, 2014; 
Jeanblanc et al., 2018; Treasure and Eid, 2019). Originally designed to study high vol-
untary EtOH consumption achieving behaviorally-intoxicating BECs, the DID model 
has been extensively used to investigate the neurobiology of binge-like EtOH intake 
(Rhodes et al., 2005; Thiele and Navarro, 2014). In the present study, we introduced a 
modified version of the DID procedure that further magnifies EtOH intake by the use of 
multiple bottles. This procedure was also shown to induce high sucrose and saccharin 
consumption. Our pharmacological data provide new evidence supporting a role of opi-
oid receptors in heightened EtOH and sweet tastant intake, suggesting common neuro-
biological pathways that may be affected as a function of enhanced consumption.  
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Although there are several variations of the DID model, one of the most fre-
quently used protocols in EtOH research involves replacing the water bottle with a tube 
containing 20% EtOH for 2-4 h, beginning 3 h into the dark cycle (Rhodes et al., 2005; 
Thiele and Navarro, 2014). With the commonly used 4-day version of this protocol, 
EtOH access is given over 2 h on days 1-3 but extended to a 4-h period on day 4 (test 
day). Using this DID protocol, different laboratories have demonstrated that genetically 
predisposed rodent strains such as B6 mice will drink up to ∼5-7 g/kg of EtOH in 4 h 
(Rhodes et al., 2005; Tarragón et al., 2012; Thiele and Navarro, 2014). This level of in-
take produces BECs higher than 100 mg/dL and induces clear signs of behavioral intox-
ication evidenced by motor impairment on the rotarod and balance beam tasks (Rhodes 
et al., 2007). It is important to mention that the National Institute on Alcohol Abuse and 
Alcoholism (2004) defines binge drinking in the context of blood alcohol concentra-
tions (≥ 80 mg/dL). Given the higher rate of metabolism, minimum BECs of 100 mg/dL 
BECs have been proposed for mice. Interestingly, Rhodes and colleagues (2007) 
demonstrated that while water availability (two-bottle choice test; water vs. 20% EtOH) 
during a 4-h test did not reduce EtOH intake, it did affect BECs (averaging less than 80 
mg/dL, as opposed to BECs greater than 120 mg/dL with access to EtOH alone). A 4-
day DID protocol with a 4-h test on day 4 using a single 20% EtOH tube has therefore 
been extensively used to investigate the biological determinants of binge-like EtOH 
drinking (see Thiele and Navarro, 2014 and Jeanblanc et al., 2018 for reviews). In our 
laboratory we have previously used a 4-h DID procedure with a single 20% EtOH tube 
(Tarragón et al., 2012) achieving 5.98 ± 0.29 g/kg of EtOH (male B6 mice). This intake 
resulted in a range in BECs of 120-140 mg/dL, with a strong positive correlation be-
tween g/kg and BECs. Similar to what was described by Rhodes et al., (2005), we found 
comparable levels of EtOH intake using single 10%, 20% or 30% EtOH tubes; mL con-
sumed across concentrations changed to achieve similar levels of g/kg (Tarragón et al., 
2012).  
Previous research has demonstrated that the number of bottles available during a 
drinking test influences EtOH intake; availability of two or more EtOH bottles of the 
same or different concentration increases EtOH intake in mice and rats (Spanagel et al., 
1996; Serra et al., 2003; Tordoff and Bachmanov, 2003a). This phenomenon has also 
been described for other taste solutions such as saccharin, citric acid, quinine and sodi-
um chloride (Tordoff and Bachmanov, 2003b). In the context of binge-like drinking, the 
use of protocols involving multiple concurrently available EtOH concentrations (2-4 
bottles), has also been shown to produce notable increases in EtOH intake in alcohol-
preferring (P) and Sardinian alcohol-preferring (sP) rats (Bell et al., 2006; Colombo et 
al., 2014), as well as in B6 and mixed B6 x 129X1/SvJ (B6x129) mice (Colozzi et al., 
2012; Fultz et al., 2017). Similarly, Shabani et al. (2016) used selectively bred meth-
amphetamine high drinking (MAHDR) mice to demonstrate that the availability of 3 
(vs. 2 or 1) bottles of methamphetamine also increased drug intake. These studies sug-
gest that for multiple rewards, greater availability leads to heightened consumption. 
Considering this evidence, we wanted to investigate whether we could boost binge-like 
EtOH intake with the concurrent availability of multiple EtOH bottles. Additionally, by 
presenting different EtOH concentrations simultaneously, we wanted to evaluate 
whether NTX would reduce overall EtOH consumption (Kamdar et al., 2007; Tarragón 
et al., 2012) or affect the pattern of EtOH intake preference across concentrations. In 
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preparation for this study, our data with B6 mice (Experiment 1) showed that a 4-day 
DID procedure (4-h test on day 4) with concurrently available 5%, 10% and 20% EtOH 
tubes produced an intake of 5.08 ± 0.35 g/kg of EtOH. We also tested concurrent 20%, 
30% and 40% EtOH, which produced a particularly high level of EtOH intake; 8.39 ± 
0.59 g/kg. In this case, intakes obtained from each tube were comparable, evidencing 
B6´s remarkable preference for highly concentrated EtOH solutions. In fact, with a sin-
gle 40% EtOH tube animals drank up to 6.87 ± 0.48 g/kg. Favoring larger differences 
across concentrations (see Fultz et al., 2017), for the present study we chose a concur-
rent 4-bottle DID procedure with 5%, 10%, 20% and 40% EtOH. With this protocol B6 
mice drank up to 9.05 ± 0.61 g/kg EtOH in 4 h (mostly from the 20% and 40% tubes); 
drinking approximately 60% of total intake (5.25 ± 0.42 g/kg) during the first 2 h. 
Compared to our own data using 4-h DID tests (current study and Tarragón et al., 2012), 
our present intake was > 2.5 g/kg higher than what we found with a single 20% EtOH 
bottle. Earlier studies using DID procedures with multiple bottles have also shown in-
creased intake when compared to single tube 20% EtOH studies. Cozzoli et al, (2012) 
demonstrated that a two-bottle DID test (concurrent 5% and 20% EtOH) produced in-
takes of ~5 g/kg (2 h) in B6x129 mice. Particularly relevant for the present study are the 
data presented by Fultz et al. (2017) with the same four concentrations used here; they 
showed impressive 2-h DID intakes of ~6 g/kg in B6 and ~7.5 g/kg in B6x129 male 
mice in 2 h. Altogether, these data indicate that multiple bottle choice DID procedures 
can produce particularly high EtOH intakes. Whether this high drinking behavior is as-
sociated with availability of different concentrations, the number of tubes that are pre-
sented, or both, will need to be elucidated in future experiments.  
It is important to mention that in the present study we did not measure BECs. 
However, given our previous data (Tarragón et al., 2012) and those published by others 
(see Crabbe et al., 2011), we can definitely suggest that the intakes of EtOH seen here 
would be expected to exceed 100 mg/dL. It is also relevant to point out that our data 
reflect intakes averaged over a period of 4 weeks (four, 4-day cycles; 4 days of EtOH 
availability followed by 3 days with no EtOH exposure). It could be argued that the in-
takes reported here were influenced by escalated drinking over repeated cycles of drink-
ing and withdrawal. Although this effect has been previously reported in B6 (Fultz et 
al., 2017), and a trend was seen in our data, we did not find significant differences in 
overall EtOH intake across weeks 1-4 (8.34 ± 1.04 and 9.74 ± 1.32 g/kg for weeks 1 and 
4, respectively; t-test, p > 0.05). It might be possible that longer periods of time are re-
quired to find clear time-dependent differences. Wilcox et al., (2014) found changes in 
EtOH consumption when DID was extended over a period of 6 weeks; intakes of weeks 
4-6 were higher than those recorded during weeks 1-3. Additionally, this study revealed 
an interesting pattern of EtOH intake (described as ‘front-loading’ behavior) character-
ized by an increased rate of consumption during the first 15 min of the drinking session. 
The amount of EtOH drunk during the first part (first 30 min) of the session was also 
found to double from week 1 to week 6, indicating that this phenomenon developed 
over time (Wilcox et al., 2014). The use of repeated cycles of DID including multiple 
EtOH bottles might be an interesting strategy to boost binge-level drinking in future 
studies. 
The predictive validity of DID as an animal model has been tested using drugs 
approved to treat alcoholism, including the opioid receptor antagonist naltrexone 
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(NTX). NTX is known for its efficacy in reducing high alcohol drinking in relapsing 
patients (Volpicelli et al., 1992; Kiefer et al., 2003; Jonas et al., 2014). NTX, alone or in 
combination with other drugs, has been shown to reduce EtOH intake using DID 
methodology (Kamdar et al., 2007; Tarragón et al., 2012; Ripley et al., 2015; Zhou et 
al., 2019; Navarro et al., 2019). These results add to an extensive list of studies indicat-
ing that NTX reduces EtOH consumption using a variety of methodologies and animal 
models (Davidson and Amit, 1997; Sharpe and Samson 2001; Fachin-Scheit et al., 
2006), including genetically predisposed EtOH-preferring strains of rodents such as B6 
mice (Le et al., 1993, Phillips et al., 1997; Middaugh et al., 2003; Dhaher et al., 2012). 
The current study presents new evidence showing that high binge-like EtOH drinking 
can be reduced by NTX. In particular, a reduction in intake was seen at the doses of 
NTX 8 and 16 mg/kg, but not 4 mg/kg. We have previously shown reductions in EtOH 
drinking with NTX 4 mg/kg using DID tests with a single 20% EtOH tube (Tarragón et 
al., 2012), an effect also found by Kamdar and colleagues (2007) with NTX 2 mg/kg. 
The particularly high intake of EtOH found with our procedure may be associated with 
the fact that higher doses of NTX were needed to reduce EtOH consumption. Consistent 
with this, Crabbe et al. (2017) showed that NTX 10 mg/kg failed to reduce EtOH drink-
ing in mice selectively bred for their high BECs using a DID procedure (HDID mice), 
which also showed high EtOH intake. Additionally, we observed a stronger, dose-de-
pendent NTX effect during the first 2 h; NTX reduced consumption of those concentra-
tions that capitalized intake (EtOH 20% and 40%). However, during the second 2 h, an 
increased preference for the highest EtOH concentration diminished the overall effect of 
NTX. As a result, for the total 4-h period, a reduced 20%, but not 40% EtOH intake was 
found with NTX 16 mg/kg. By increasing intake from the most pharmacologically effi-
cient EtOH tube (40%), B6 mice might have tried to oppose the reward-reducing effects 
of a high NTX dose. Overall, the present DID data support extensive evidence propos-
ing a role of the endogenous opioid system in the neurobiology that mediates EtOH 
drinking (Gianoulakis, 2001; Font et al., 2013). Future studies will need to elucidate the 
involvement of mu-, delta- and/or kappa-opioid receptors using EtOH DID protocols. 
Mice lacking the pro-opiomelanocortin (POMc)-derived peptide beta-endorphin showed 
reduced DID using 7.5%, 15% or 30% EtOH solutions, suggesting a pivotal role of mu- 
and delta-opioid receptors (Zhou et al., 2017a). 
The endogenous opioid system has also been linked to sugar and other sweet 
rewards (Kelley et al., 2002; Olszewski and Levine, 2007; Berridge and Kringelbach, 
2015). Intake of saccharin solutions increases by infusions of a mu opioid agonist into 
the ventral striatum (Zhang and Kelley, 2002), and pharmacological antagonism of opi-
oid receptors can reduce consumption of sucrose and saccharin (Biggs and Myers, 1998; 
June et al., 2004; Morales et al., 2017). Also, excessive sugar intake can produce with-
drawal-like symptoms associated with alterations in opioid receptor signaling (Colan-
tuoni et al., 2002; Avena et al., 2009). In our study, B6 mice showed remarkably high 
intakes of sucrose, drinking up to 32.75 ± 1.40 g/kg in 4 h (0-2 h; 19.5 ± 1.39 g/kg, and 
2-4 h; 13.25 ± 1.10 g/kg). Our previous data using a 2-h 10% sucrose DID test showed 
that B6 mice consumed ∼6.8-8.2 g/kg (Tarragón et al., 2012). In our current study, in-
take (both in mL and g/kg) was obtained almost exclusively from the 40% tube. Our 
pilot studies (data not shown) revealed that, regardless of the combination of concentra-
tions, mice always obtained most of their intake from the highest sucrose concentration 
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available. Due to extreme solution viscosity we did not use concentrations higher than 
40%. With our procedure, we found that the two highest doses of NTX (8 and 16 mg/
kg) reduced sucrose drinking, an effect mostly seen during the first 2 h of the 4-h test. 
Studies using less concentrated solutions (i.e, 10%) and lower doses of NTX have re-
ported no effects of this antagonist on DID sucrose consumption (Kamdar et al., 2007; 
Tarragón et al., 2012). Future studies will need to clarify whether, as the current data 
suggest, the effect of NTX on sucrose DID requires higher levels of binge-like intake 
and/or higher doses of NTX.  
High saccharin intake was also achieved with our multiple-bottle DID protocol, 
reaching 0.72 ± 0.05 g/kg in 4 h (0-2 h; 0.42 ± 0.04 g/kg, and 2-4 h; 0.30 ± 0.03 g/kg). 
This intake was significantly higher than what has been previously reported with other 
DID experiments that used lower concentrations. Using 0.1% saccharin, Zhou et al. 
(2019) found intakes around 0.1 g/kg in 4 h (male B6), while Kamens et al. (2018) 
showed drinking up to ∼0.02 g/kg in 2 h (adolescent male and female B6; 0.033% sac-
charin). Our animals preferred the concentration of 1.06%. However, this preference for 
the highest concentration was not as skewed as that observed with sucrose. Approxi-
mately 50% and 20% of total intake (mL) was obtained from the 1.06% and 0.53% 
tubes, respectively. To the best of our knowledge, the current study presents the first 
data showing that NTX reduces saccharin intake using a DID procedure. A combination 
of bupropion 10 mg/kg + NTX 1 mg/kg, capable of reducing 4% sucrose intake, did not 
affect 0.1% saccharin DID consumption (Zhou et al., 2019). However, previous re-
search using non-DID procedures has found that opioid receptor antagonism can reduce 
saccharin intake (Lynch and Libby, 1983; Chow et al., 1997; Biggs and Myers, 1998). 
In our case, high saccharin DID was particularly resistant to the effects of NTX; we had 
to administer 16 mg/kg of NTX to see a reduction in overall intake. Similar to what we 
found with sucrose, this effect was mostly observed during the first 2 h. Concentration-
dependent analyses showed that NTX 8 mg/kg also reduced intake of 1.06% during the 
first 2 h. Interestingly, during the 2-4 h period, NTX 16 mg/kg increased intake of sac-
charin 0.53% (in mL) and did not reduce 1.06% drinking. This effect mirrors our find-
ings in the EtOH study and might reflect compensatory mechanisms aimed to outweigh 
the effects of NTX.  
One advantage of multiple-bottle drinking procedures is that they can also be 
used to assess intake preferences across different solutions. In the present study we in-
vestigated consumption of low concentrations of sucrose (5%) and saccharin (0.13%) 
concurrently available with 20% EtOH. Mice preferred sweet solutions over EtOH, 
overall consuming most from the saccharine option, followed by sucrose. In comparison 
to our single tastant studies, total intakes were significantly higher for this experiment, 
with values exceeding 4.5 mL in 4 h. Perhaps the fact that sucrose and saccharin were 
offered at lower concentrations allowed them to drink more volume. This elevated 
drinking prompted us to examine water intake during the remaining 20 h (non-experi-
mental phase), finding that mice consumed ∼90% of their daily fluid intake during the 
4-h DID test (data not shown). It is also interesting to point out that, with this combina-
tion of solutions, total intakes during the first and second 2-h periods were comparable. 
This differs from our single solution experiments where animals tended to ‘front-load’ 
intakes in the first 2 h period. In addition, the effect of NTX on intake with three differ-
ent solutions was also different. We found that all NTX doses, including 4 mg/kg, re-
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duced intake (overall 4-h drinking), and this effect was particularly significant during 
the second 2 h of the test. Sucrose and saccharin intakes were not differentially affected 
by NTX. This is important to highlight because this experiment was originally designed 
to evaluate whether NTX would produce differential effects on intake when animals can 
choose between caloric (EtOH, sucrose) and non-caloric (saccharin) solutions. Our data 
suggest that both, taste and post-ingestive aspects of sucrose and saccharin intake can be 
regulated by opioid receptors. It has been argued that homeostatic factors can affect 
DID (Tabarin et al. 2007; Thiele and Navarro, 2014). However, manipulations to the 
homeostatic state of animals, either by food deprivation or pharmacological manipula-
tions of molecules that influence appetite have all failed to alter the high levels of EtOH 
intake produced by the DID procedure (Lyons et al., 2008). This suggests that such lev-
els of consumption are likely to be driven by the reinforcing pharmacological effects of 
EtOH. The ability of NTX to reduce intake is therefore likely due to its ability to inter-
fere with such reinforcing properties of EtOH. Future experiments with food-deprived 
and sated animals might help clarify the role of the opioid system in modulating sucrose 
and saccharin binge-like drinking using DID methodology. 
Concluding remarks and future directions  
Drug abuse and binge eating disorders share imbalances in brain systems that 
regulate motivation, reward saliency, decision-making, and self-control (Volkow et al., 
2017; Wiss et al., 2018). Together with mesolimbic dopamine, the endogenous opioid 
system has been shown to play an important role in regulating food and drug reward 
(Volkow et al., 2013, 2017; Berridge and Kringelbach, 2015). Clinical evidence indi-
cates that endogenous opioids promote intake of sweet and fat tastants, and a polymor-
phism of the mu opioid receptor gene has been associated with binge eating disorders 
(Davis et al., 2009; Olszewski et al., 2011; Volkow et al., 2013, 2017). In the current 
study we introduced a modified version of an animal model of binge-like intake (DID) 
that produces notably high consumption of EtOH, sucrose and saccharin, and present 
evidence of an involvement of opioid receptors in such intakes. This high binge-like 
intake-promoting procedure expands our methodological options to investigate over-
consumption of palatable foods and addictive substances. In future studies, it could be 
used to investigate the role of sex, energy homeostasis, history of drug experience as 
well as to test new pharmacological tools in the context of binge intake research. 
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Table 1. Effects of naltrexone (NTX) on EtOH intake (mL ± SEM) 
Top panel shows the effects of NTX (0, 4, 8 or 16 mg/kg) on total EtOH intake (mL) collapsed 
across different concentrations for the 0-2 h, 2-4 h, and 0-4 h time periods; *p < 0.05 different 
from 0 mg/kg, **p < 0.01 different from 0 and 4 mg/kg. Bottom panels show the effects of NTX 
on EtOH drunk from each individual tube (concentration); *p < 0.05, **p < 0.01 relative to 0 
mg/kg for each respective time period and concentration. For the 20% EtOH, 16 mg/kg NTX 
groups **p < 0.01 also indicates different from 4 mg/kg (2-4 h and 0-4 h time periods).  
  
NTX Dose (mg/kg)
Time (h) 0 4 8 16
Total 
Intake 
0-2 0.74 ± 0.07 0.53 ± 0.05 0.44 ± 0.05 0.37 ± 0.07
2-4 0.57 ± 0.05 0.55 ± 0.06 0.45 ± 0.06 0.33 ± 0.05
0-4 1.31 ± 0.11 1.08 ± 0.10 0.89 ± 0.06* 0.70 ± 0.12**
Time (h) Concentration 
0-2 5% 0.10 ± 0.02 0.06 ± 0.02 0.06 ± 0.02 0.07 ± 0.02
10% 0.13 ± 0.03 0.09 ± 0.03 0.11 ± 0.02 0.08 ± 0.04
20% 0.28 ± 0.04 0.17 ± 0.03 0.15 ± 0.03* 0.09 ± 0.02**
40% 0.23 ± 0.02 0.21 ± 0.02 0.12 ± 0.02 0.13 ± 0.03
2-4 5% 0.07 ± 0.02 0.08 ± 0.02 0.09 ± 0.03 0.06 ± 0.03
10% 0.10 ± 0.03 0.08 ± 0.02 0.15 ± 0.04 0.07 ± 0.02
20% 0.25 ± 0.03 0.23 ± 0.04 0.14 ± 0.01 0.07 ± 0.03**
40% 0.15 ± 0.01 0.16 ± 0.02 0.07 ± 0.02 0.13 ± 0.04
0-4 5% 0.17 ± 0.03 0.14 ± 0.04 0.15 ± 0.03 0.13 ± 0.04
10% 0.23 ± 0.04 0.17 ± 0.04 0.26 ± 0.05 0.15 ± 0.04
20% 0.53 ± 0.06 0.40 ± 0.06 0.29 ± 0.03** 0.16 ± 0.03**
40% 0.38 ± 0.02 0.37 ± 0.03 0.19 ± 0.03* 0.26 ± 0.07
Table 2. Effects of naltrexone (NTX) on sucrose intake (mL ± SEM) 
Top panel indicates effects of NTX on overall sucrose consumption (mL) during the three time 
periods observed; *p < 0.05 and **p < 0.01 relative to 0 mg/kg. The NTX 16 mg/kg group (0-4 
h) was also different (p < 0.05) from NTX 4 mg/kg for the same time period. Concentration-
specific effects of NTX are show on lower panels; **p < 0.01 indicates differences compared to 
NTX 0. For 40% sucrose, NTX 8 and 16 mg/kg groups were also different (p < 0.05) from NTX 
4 mg/kg during the 0-2 h and 0-4 h time periods. 
NTX Dose (mg/kg)
Time (h) 0 4 8 16
Total 
Intake
0-2 1.29 ± 0.08 1.15 ± 0.06 0.95 ± 0.09* 0.64 ± 0.09**
2-4 0.86 ± 0.09 0.80 ± 0.04 0.75 ± 0.06 0.87 ± 0.09
0-4 2.15 ± 0.09 1.95 ± 0.07 1.70 ± 0.10* 1.51 ± 0.16**
Time (h) Concentration 
0-2 5% 0.05 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 0.02 ± 0.01
10% 0.03 ± 0.01 0.04 ± 0.01 0.05 ± 0.03 0.02 ± 0.01
20% 0.07 ± 0.02 0.05 ± 0.03 0.05 ± 0.03 0.03 ± 0.03
40% 1.14 ± 0.08 1.03 ± 0.07 0.83 ± 0.07** 0.57 ± 0.08**
2-4 5% 0.02 ± 0.01 0.01 ± 0.01 0.03 ± 0.02 0.05 ± 0.03
10% 0.04 ± 0.03 0.01 ± 0.01 0.02 ± 0.01 0.01 ± 0.01
20% 0.02 ± 0.01 0.03 ± 0.03 0.05 ± 0.02 0.04 ± 0.02
40% 0.78 ± 0.06 0.75 ± 0.05 0.65 ± 0.08 0.77 ± 0.11
0-4 5% 0.07 ± 0.02 0.04 ± 0.01 0.05 ± 0.02 0.07 ± 0.03
10% 0.07 ± 0.03 0.05 ± 0.02 0.07 ± 0.03 0.03 ± 0.01
20% 0.09 ± 0.02 0.08 ± 0.05 0.10 ± 0.05 0.07 ± 0.05
40% 1.92 ± 0.09 1.78 ± 0.09 1.48 ± 0.12** 1.34 ± 0.17**
Table 3. Effects of naltrexone (NTX) on saccharine intake (mL ± SEM) 
Top section indicates total volume of saccharine drank after each NTX (0, 4, 8 or 16 mg/kg) 
dose. NTX 16 mg/kg decreased saccharine drinking (*p < 0.05 relative to NTX 0 mg/kg) during 
the first 2-h block. When individual concentrations were considered, the highest dose of NTX 
decreased intake of 1.06% and increase 0.53% saccharine solutions (**p < 0.01 relative to 0 mg/
kg for each respective time period).  
NTX Dose (mg/kg)
Time (h) 0 4 8 16
Total  
Intake
0-2 1.59 ± 0.11 1.35 ± 0.11 1.27 ± 0.07 1.15 ± 0.17*
2-4 1.13 ± 0.11 1.19 ± 0.13 1.24 ± 0.12 1.39 ± 0.13
0-4 2.72 ± 0.18 2.54 ± 0.20 2.51 ± 0.15 2.54 ± 0.27
Time (h) Concentration 
0-2 0.13% 0.20 ± 0.05 0.15 ± 0.04 0.14 ± 0.04 0.11 ± 0.02
0.26% 0.24 ± 0.04 0.24 ± 0.08 0.24 ± 0.04 0.21 ± 0.05
0.53% 0.37 ± 0.07 0.35 ± 0.06 0.36 ± 0.06 0.51 ± 0.17
1.06% 0.78 ± 0.11 0.61 ± 0.08 0.53 ± 0.08 0.32 ± 0.07**
2-4 0.13% 0.18 ± 0.04 0.16 ± 0.07 0.12 ± 0.03 0.12 ± 0.04
0.26% 0.15 ± 0.04 0.22 ± 0.06 0.18 ± 0.04 0.23 ± 0.06
0.53% 0.27 ± 0.04 0.33 ± 0.07 0.41 ± 0.08 0.63 ± 0.14**
1.06% 0.53 ± 0.07 0.48 ± 0.07 0.53 ± 0.07 0.41 ± 0.08
0-4 0.13% 0.38 ± 0.08 0.31 ± 0.08 0.26 ± 0.07 0.23 ± 0.05
0.26% 0.39 ± 0.07 0.46 ± 0.14 0.42 ± 0.07 0.44 ± 0.10
0.53% 0.64 ± 0.10 0.68 ± 0.12 0.77 ± 0.12 1.14 ± 0.29
1.06% 1.31 ± 0.15 1.09 ± 0.11 1.06 ± 0.13 0.73 ± 0.14**
Table 4. Effects of naltrexone (NTX) on sucrose, saccharin and ethanol (EtOH) intake (mL ± 
SEM) 
Table 4 shows total saccharin, sucrose and EtOH drinking (simultaneously available) after NTX 
treatment (0, 4, 8 or 16 mg/kg). Top panel; all NTX doses (4, 8, 16 mg/kg) decreased total 
solution consumption during the 4-h test period; *p < 0.05 and **p < 0.01 relative to NTX 0 mg/
kg. Bottom panels show individual tastant consumptions as a function of time and NTX dose. 
NTX Dose (mg/kg)
Time (h) 0 4 8 16
Total 
Intake 
0-2 2.34 ± 0.19 1.80 ± 0.18 1.84 ± 0.17 1.96 ± 0.10
2-4 2.57 ± 0.16 2.00 ± 0.18 1.74 ± 0.11 2.02 ± 0.09
0-4 4.91 ± 0.30 3.80 ± 0.32** 3.58 ± 0.26** 3.98 ± 0.18*
Time (h) Tastant  
0-2 Saccharin 0.13% 1.41 ± 0.13 1.12 ± 0.14 1.23 ± 0.13 1.24 ± 0.10
Sucrose 5% 0.81 ± 0.12 0.61 ± 0.10 0.46 ± 0.08 0.63 ± 0.09
EtOH 20% 0.12 ± 0.07 0.07 ± 0.02 0.15 ± 0.07 0.09 ± 0.05
2-4 Saccharin 0.13% 1.57 ± 0.10 1.28 ± 0.12 1.17 ± 0.09 1.31 ± 0.10
Sucrose 5% 0.92 ± 0.12 0.67 ± 0.10 0.47 ± 0.05 0.60 ± 0.08
EtOH 20% 0.08 ± 0.03 0.05 ± 0.02 0.10 ± 0.07 0.11 ± 0.07
0-4 Saccharin 0.13% 2.98 ± 0.20 2.40 ± 0.22 2.40 ± 0.20 2.55 ± 0.17
Sucrose 5% 1.73 ± 0.22 1.28 ± 0.19 0.93 ± 0.12 1.23 ± 0.15
EtOH 20% 0.20 ± 0.07 0.12 ± 0.02 0.25 ± 0.10 0.20 ± 0.08
Figure Legends 
Figure 1. EtOH intake (g/kg) as a function of EtOH concentration availability. 
Intakes obtained with separate groups (n=12-15) with access (4 h) to one, three or four 
EtOH tubes. From left to right, bars (mean ± SEM) represent access to: A, one tube with 
20% EtOH; B, one tube with 40% EtOH; C, three simultaneously available tubes with 
5%, 10% and 20% EtOH; D, three simultaneously available tubes with 20%, 30% and 
40% EtOH; E, four simultaneously available tubes with 5%, 10%, 20% and 40% EtOH. 
*p < 0.05, **p < 0.01 indicates different from A. Group E was also found to be different 
from B (p < 0.05). 
Figure 2. Effects of naltrexone (NTX) on EtOH intake (g/kg). Panel A shows the 
effect of NTX (0, 4, 8 or 16 mg/kg) on total EtOH intake (collapsed on concentration) 
during 0-2 h, 2-4 h and 0-4 h time periods. Panels B, C and D show NTX effects on 
EtOH intake as a function of concentration for the two 2-h periods and total 0-4 h 
period, respectively. *p < 0.05, **p < 0.01 indicates different from NTX 0 mg/kg at the 
same EtOH concentration. Bars represent mean ± SEM; n = 15 per group. 
      
Figure 3. Effects of naltrexone (NTX) on sucrose intake (g/kg). Effects of NTX for 
total intakes during 0-2 h, 2-4 h and 0-4 h time periods, combining all sucrose 
concentrations, are shown on panel A; *p < 0.05, different from NTX 0 mg/kg for each 
respective time period. Panels B, C and D show NTX effects on sucrose intake as a 
function of concentration during the two 2-h periods and total 0-4 h period, respectively. 
**p < 0.01 indicates different from NTX 0 mg/kg at the same EtOH concentration. Bars 
represent mean ± SEM; n = 15 per group. 
Figure 4. Effects of naltrexone (NTX) on saccharin intake (g/kg). Panel A shows the 
effect of NTX on total intake (combining all saccharin concentrations) during the 0-2 h, 
2-4 h and 0-4 h time periods; *p < 0.05, different from NTX 0 mg/kg for each 
respective time period. Panels B, C and D show NTX effects on saccharin intake at 
different concentrations and the effects of NTX during the two 2-h periods and total 0-4 
h period, respectively. *p < 0.05, **p < 0.01 indicates different from NTX 0 mg/kg at 
the same EtOH concentration. Bars represent mean ± SEM; n = 16 per group. 
  
Figure 5. Effects of naltrexone (NTX) on simultaneously available saccharin (S), 
sucrose (SU) and EtOH (E) intake (ml/g). Effects of NTX on total intakes during 0-2 
h, 2-4 h and 0-4 h time periods, combining ml drank from saccharin, sucrose and EtOH 
tubes are shown on panel A; *p < 0.05, **p < 0.01 different from NTX 0 mg/kg. Panels 
B, C and D show NTX effects on the three different drinking solutions during the two 2-
h periods and total 0-4 h period, respectively. Bars represent mean ± SEM; n = 15 per 
group. 
      
      
      





